| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/02/2009 | EP2095127A1 Methods for screening and treatment involving the genes gypc, agpat3, agl, pvrl2, hmgb 3, hsdl2 and/or ldb2 |
| 09/02/2009 | EP2094866A2 Diagnosis and treatment of breast cancer |
| 09/02/2009 | EP2094849A2 Long term disease modification using immunostimulatory oligonucleotides |
| 09/02/2009 | EP2094715A2 Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon |
| 09/02/2009 | EP2094714A2 Substituted thienopyridone compounds with antibacterial activity |
| 09/02/2009 | EP2094713A1 Epothilone analogues modified at positions c12-c13 as anticancer drugs |
| 09/02/2009 | EP2094711A1 Structural mimetics of proline-rich peptides and the pharmaceutical use thereof |
| 09/02/2009 | EP2094709A1 Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| 09/02/2009 | EP2094708A2 A pyrrolopyrazin as syk-kinase inhibitor |
| 09/02/2009 | EP2094707A1 Heterobicyclic matrix metalloprotease inhibitors |
| 09/02/2009 | EP2094706A2 Substituted 2,5-dfflydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and use of same as cannabinoid cb1 receptor ligands |
| 09/02/2009 | EP2094704A2 Cis-cyclohexyl substituted pyrimidinone derivatives |
| 09/02/2009 | EP2094703A1 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes |
| 09/02/2009 | EP2094702A2 Viral inhibitors |
| 09/02/2009 | EP2094701A2 Compounds and methods for kinase modulation, and indications therefor |
| 09/02/2009 | EP2094700A2 Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| 09/02/2009 | EP2094699A2 New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7 |
| 09/02/2009 | EP2094698A1 Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
| 09/02/2009 | EP2094697A1 5-sulfanylmethyl-pyrazolo [1,5-a]pyrimidin-7-ol derivatives as cxcr2 antagonists |
| 09/02/2009 | EP2094696A1 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists |
| 09/02/2009 | EP2094695A1 Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| 09/02/2009 | EP2094694A1 Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists |
| 09/02/2009 | EP2094692A2 Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| 09/02/2009 | EP2094690A2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists |
| 09/02/2009 | EP2094689A2 Indolylmaleimide derivatives as kinase inhibitors |
| 09/02/2009 | EP2094688A1 Heterocyclic compounds with cxcr3 antagonist activity |
| 09/02/2009 | EP2094687A1 3 -amino- pyridine derivatives for the treatment of metabolic disorders |
| 09/02/2009 | EP2094686A1 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl]ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc. |
| 09/02/2009 | EP2094685A2 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors |
| 09/02/2009 | EP2094684A2 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin 2-ones as cb1 receptor modulators |
| 09/02/2009 | EP2094683A2 Bicyclic compounds and use as antidiabetics |
| 09/02/2009 | EP2094682A2 Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| 09/02/2009 | EP2094681A1 Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
| 09/02/2009 | EP2094678A2 Prostaglandin prodrugs as ocular hypotensive agents |
| 09/02/2009 | EP2094677A1 Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
| 09/02/2009 | EP2094675A1 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one |
| 09/02/2009 | EP2094674A1 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one |
| 09/02/2009 | EP2094673A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 09/02/2009 | EP2094672A2 Arylsulfonamide compounds |
| 09/02/2009 | EP2094671A1 Heterobicyclic metalloprotease inhibitors |
| 09/02/2009 | EP2094669A2 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
| 09/02/2009 | EP2094668A2 4-imidazolines as taar's ligands |
| 09/02/2009 | EP2094666A1 Cannabinoid receptor modulators |
| 09/02/2009 | EP2094665A2 Preparation of montelukast and its salts |
| 09/02/2009 | EP2094663A2 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| 09/02/2009 | EP2094662A1 Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents |
| 09/02/2009 | EP2094660A2 Immunochemically equivalent hiv drug analogs |
| 09/02/2009 | EP2094657A1 Azabicyclic compounds as serotonine, dopamine and norepinephrine re-uptake inhibitors |
| 09/02/2009 | EP2094656A2 P<0}{0pyrrol derivatives, preparation and use of the same in therapy<0} |
| 09/02/2009 | EP2094655A1 Novel biphenyl thio-urea derivatives useful as potassium channel modulators |
| 09/02/2009 | EP2094653A1 O-substituted-dibenzyl urea-derivatives as trpv1 receptor antagonists |
| 09/02/2009 | EP2094651A1 Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| 09/02/2009 | EP2094646A1 Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases |
| 09/02/2009 | EP2094645A1 2-hydroxy-1,3-diaminopropane derivatives |
| 09/02/2009 | EP2094643A2 N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| 09/02/2009 | EP2094640A1 Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar). |
| 09/02/2009 | EP2094358A2 Imidazoles for treating multi-drug resistant bacterial infections |
| 09/02/2009 | EP2094309A2 Alpha-lactalbumin composition |
| 09/02/2009 | EP2094308A1 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| 09/02/2009 | EP2094289A1 Conjoint therapy for treating fibrotic diseases |
| 09/02/2009 | EP2094287A1 Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye |
| 09/02/2009 | EP2094283A1 Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications |
| 09/02/2009 | EP2094280A1 Pharmaceutical agent having long-lasting effect of treating arthritic disorders |
| 09/02/2009 | EP2094279A2 Methods and compositions for treating influenza |
| 09/02/2009 | EP2094278A1 Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
| 09/02/2009 | EP2094277A1 A composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them |
| 09/02/2009 | EP2094276A2 Anti-viral compounds |
| 09/02/2009 | EP2094275A2 Methods and formulations for improved bioavailability of antiprogestins |
| 09/02/2009 | EP2094273A1 Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| 09/02/2009 | EP2094272A2 Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors |
| 09/02/2009 | EP2094271A2 Drug combinations for treating airway diseases |
| 09/02/2009 | EP2094270A1 Delivery system for risperidone |
| 09/02/2009 | EP2094269A1 Pyrrolidinanilines |
| 09/02/2009 | EP2094268A2 Drug combinations with substituted diaryl ureas for the treatment of cancer |
| 09/02/2009 | EP2094267A2 4-(1-amino-ethyl)-cyclohexylamine derivatives |
| 09/02/2009 | EP2094266A1 Crth2 antagonists |
| 09/02/2009 | EP2094265A1 Pyrroloy[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents |
| 09/02/2009 | EP2094264A1 Clotrimazol for treating staphylococcal infections |
| 09/02/2009 | EP2094263A1 2-adamantyl-butyramide derivatives as selective 11 beta-hsd1 inhibitors |
| 09/02/2009 | EP2094262A1 Pharmaceutical composition containing phenanthrenequinone-based compound for intestine delivery system |
| 09/02/2009 | EP2094261A1 Pharmaceutical composition containing naphthoquinone-based compound for intestine delivery system |
| 09/02/2009 | EP2094259A1 Renin inhibitors for the prevention and treatment of hypertension in obese patients |
| 09/02/2009 | EP2094258A1 Pharmaceutical composition using aliskiren and avosentan |
| 09/02/2009 | EP2094257A1 Methods for improving bioavailability of a renin inhibitor |
| 09/02/2009 | EP2094256A1 Method for alleviating keratoconjunctivitis sicca |
| 09/02/2009 | EP2094255A1 Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature |
| 09/02/2009 | EP2094254A1 Treatment of cachexia |
| 09/02/2009 | EP2094253A1 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| 09/02/2009 | EP2094252A1 Nutritional supplement composition for treatment of ocular diseases |
| 09/02/2009 | EP2094249A2 Transdermal therapeutic system for administering the active substance buprenorphine |
| 09/02/2009 | EP2094248A2 Ibuprofen composition |
| 09/02/2009 | EP2094246A1 Sustained-release composition and method for producing the same |
| 09/02/2009 | EP2094245A2 Stable powder formulation containing a novel anticholinergic agent |
| 09/02/2009 | EP2094242A2 Matrix-embedded compositions having organic acids and fatty acids |
| 09/02/2009 | EP2094241A2 Oral formulations |
| 09/02/2009 | EP2094235A2 Ocular devices and methods of making and using thereof |
| 09/02/2009 | EP2094116A1 Solid or aqueous alkaline preparation comprising a creatine component, process for the production thereof and the use thereof |
| 09/02/2009 | EP2094085A2 Anti-cholesterolemic compounds and methods of use |
| 09/02/2009 | EP2094084A2 Process for making crystalline anhydrous docetaxel |
| 09/02/2009 | EP2094081A1 Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |